We have located links that may give you full text access.
COMPARATIVE STUDY
JOURNAL ARTICLE
Susceptibility of MDR Pseudomonas aeruginosa to ceftolozane/tazobactam and comparison of different susceptibility testing methods.
Journal of Antimicrobial Chemotherapy 2017 November 2
BACKGROUND: Infections caused by MDR Pseudomonas aeruginosa are on the rise, particularly in critically ill patients. Therefore, there is a need to evaluate new antimicrobial regimens. The objectives of this study were to investigate the ceftolozane/tazobactam resistance rates of MDR and XDR P. aeruginosa, the underlying resistance genes, the clonal structure and different antimicrobial susceptibility testing (AST) methods regarding their accuracy for ceftolozane/tazobactam testing.
METHODS: In total, 112 MDR and XDR P. aeruginosa (from infection and colonization) from one German tertiary care hospital were included (2013-16). AST was done using broth microdilution (BMD), gradient diffusion test strips and disc diffusion. Resistance genes were screened by PCR. A randomly selected subset of 77 isolates was subjected to WGS to assess the clonal structure.
RESULTS: In total, 38 isolates (33.9%) were resistant to ceftolozane/tazobactam according to the BMD reference method. Resistance was significantly lower in MDR P. aeruginosa (4.8%) compared with XDR P. aeruginosa (50%, P < 0.0001). The underlying mechanism in carbapenemase-positive ceftolozane/tazobactam-resistant isolates (n = 38) was blaIMP (n = 25), blaVIM (n = 4) and blaGES (n = 1). The resistance mechanism of the remaining eight ceftolozane/tazobactam-resistant isolates remained unclear. Although our strain collection was diverse, resistance to ceftolozane/tazobactam was almost exclusively associated with MLST ST235. The disc diffusion method was accurate for ceftolozane/tazobactam AST (no false-susceptible results, categorical agreement = 92.9%).
CONCLUSIONS: Ceftolozane/tazobactam resistance was low in MDR P. aeruginosa, but higher in XDR P. aeruginosa. The disc diffusion method showed an acceptable accuracy for ceftolozane/tazobactam AST.
METHODS: In total, 112 MDR and XDR P. aeruginosa (from infection and colonization) from one German tertiary care hospital were included (2013-16). AST was done using broth microdilution (BMD), gradient diffusion test strips and disc diffusion. Resistance genes were screened by PCR. A randomly selected subset of 77 isolates was subjected to WGS to assess the clonal structure.
RESULTS: In total, 38 isolates (33.9%) were resistant to ceftolozane/tazobactam according to the BMD reference method. Resistance was significantly lower in MDR P. aeruginosa (4.8%) compared with XDR P. aeruginosa (50%, P < 0.0001). The underlying mechanism in carbapenemase-positive ceftolozane/tazobactam-resistant isolates (n = 38) was blaIMP (n = 25), blaVIM (n = 4) and blaGES (n = 1). The resistance mechanism of the remaining eight ceftolozane/tazobactam-resistant isolates remained unclear. Although our strain collection was diverse, resistance to ceftolozane/tazobactam was almost exclusively associated with MLST ST235. The disc diffusion method was accurate for ceftolozane/tazobactam AST (no false-susceptible results, categorical agreement = 92.9%).
CONCLUSIONS: Ceftolozane/tazobactam resistance was low in MDR P. aeruginosa, but higher in XDR P. aeruginosa. The disc diffusion method showed an acceptable accuracy for ceftolozane/tazobactam AST.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app